Ensysce Biosciences, Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Information concerning the sale of unregistered securities in April 2025 was disclosed in a Current Report on Form 8-K filed on April 24, 2025.
On April 7, 2025, the Company entered into an agreement with a former independent contractor to resolve a dispute over payment, pursuant to which the Company issued 20,000 shares, bearing a restrictive legend, as compensation. The issuance involved no underwriters, underwriting discounts or commissions, or public offering and was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act (and Regulation D promulgated thereunder) as a transaction by an issuer not involving any public offering.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.